Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Zolbetuximab with chemotherapy for untreated CLDN 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction cancer have been revised. It is anticipated that the appraisal will begin in early-August 2023 when we will write to you about how you can get involved.